Newsletter Signup x
T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive and hard to treat cancer. CAR-T cell therapy has done an incredible job in improving survival rates for some cancer types, but it has been difficult to develop a CAR-T cell therapy against T-ALL that doesn’t also result in dangerous side-effects. Dr Marc Mansour and his team hope to produce the first CAR T-cells that can safely treat T-ALL cells without harming healthy cells.
Exploiting a novel immunotherapy target for the treatment of T-cell acute lymphoblastic leukaemia (T-ALL)
Dr Marc Mansour
UCL Cancer Institute
London WC1E 6DD
14 September 2020
36 months
£249,324.87
Patient Story – Esme
Esme had just turned three when a number of symptoms eventually led to a diagnosis of acute lymphoblastic leukaemia
Read more